Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wood Group to be investigated by FCA

(Sharecast News) - Wood Group said on Friday that the Financial Conduct Authority has launched an investigation into the company for the period from 1 January 2023 to 7 November 2024. In a very brief statement, it said: "The company will cooperate fully with the FCA in relation to this investigation."

Wood Group announced in November last year that it had agreed to commission an independent review by Deloitte following the exceptional contract write-offs relating to the exit from lump sum turnkey and large-scale EPC reported at the half-year 2024 results.

It said at the time that the review would focus on reported positions on contracts in Projects, accounting, governance and controls, including whether any prior year restatement may be required.

Shares in the company then tumbled in March 2025 when it said the review had found "material weakness and failures" in its books.

Wood said at the time: "As a result of the review, Wood has identified material weaknesses and failures in the group's financial culture within the Projects business unit and engagement between Group Finance and Projects.

"This included inappropriate management pressure and override to maintain previously reported positions, including through unsupported dispensations, and over-optimism and/or lack of evidence in respect of accounting judgements. The cultural failings appear to have led to instances of information being inappropriately withheld from, and unreliable information being provided to, Wood's auditors."

The engineering firm said that "material" prior year profit & loss and balance sheet adjustments were expected for FY22, FY23 and HY24. It also said it expected "material" restatements for adjusted EBITDA and adjusted EBIT for FY22 and FY23.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.